Vincerx Pharma Stock Set to Reverse Split on Tuesday, January 28th (NASDAQ:VINC)

Vincerx Pharma, Inc. (NASDAQ:VINC)’s stock is set to reverse split before the market opens on Tuesday, January 28th. The 1-20 reverse split was announced on Thursday, January 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, January 27th.

Vincerx Pharma Price Performance

VINC traded down $0.03 during midday trading on Friday, hitting $0.10. 7,380,350 shares of the company’s stock traded hands, compared to its average volume of 4,778,677. The company has a market cap of $3.50 million, a PE ratio of -0.10 and a beta of 1.48. The stock’s fifty day simple moving average is $0.22 and its 200-day simple moving average is $0.46. Vincerx Pharma has a one year low of $0.10 and a one year high of $9.37.

Analysts Set New Price Targets

Separately, Leerink Partners cut their price target on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Institutional Trading of Vincerx Pharma

An institutional investor recently bought a new position in Vincerx Pharma stock. Armistice Capital LLC bought a new position in Vincerx Pharma, Inc. (NASDAQ:VINC) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned about 6.70% of Vincerx Pharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 44.02% of the company’s stock.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.